The move is intended to complement Philips’ Therapeutic Care unit with the addition of RDT’s connected emergency care solutions portfolio.
Philips Therapeutic Care consists of Emergency Care & Resuscitation and Hospital Respiratory Care businesses.
The RDT portfolio comprises ambulance and emergency responders, including a monitor and defibrillator called Tempus ALS. The company also provides lightweight monitors that enable telecommunication.
Philips expects that the acquisition will aid in catering to the €1.4bn resuscitation and emergency care market, while bolstering its digital transformation capabilities for healthcare and new market entry.
Royal Philips Therapeutic Care business leader Arman Voskerchyan said: “We are committed to investing in and expanding our resuscitation and emergency care offering, and with the acquisition of RDT we can boost our capabilities and portfolio in this vital area of healthcare.
“With its focus on the pre-hospital market, RDT’s portfolio of emergency care solutions will enable Philips to grow its presence in this market, as we further build our health technology portfolio and extend the range of connected, data-driven solutions we offer to our customers.”
Currently, Philips supplies monitoring and therapeutic solutions for emergency medical services, hospitals and lay responders.
Its portfolio includes automated external defibrillators (AEDs), advanced life support monitors and data management solutions.
RDT CEO Graham Murphy said: “Our mission is very much aligned with Philips’ own, as we are committed to transforming the delivery of care and improving patient outcomes driven by customer-focused innovation.
“Together, we will continue to enable prehospital caregivers to make a real difference to patient outcomes everywhere.”
Established in 1997, RDT operates in Europe and North America with a total of up to 100 employees.